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Background/Aims.Pancreaticductaladenocarcinoma(PDA)hasetiologicalassociationwithchronicinﬂammation.Elevatedcircu-
lating levels of inﬂammatory mediators, such as monocyte chemoattractant protein-1 (MCP-1), are found in obese individuals.
We hypothesized that serum MCP-1 levels are elevated in obese PDA patients. Methods. ELISA was used to analyze MCP-1 serum
levels in PDA (n = 62) and intraductal papillary mucinous neoplasms (IPMN) (n = 27). Recursive partitioning statistical analysis
investigated the relationship between log MCP-1 and clinicopathological parameters. Results. Log MCP-1 values were signiﬁcantly
(P<0.05) elevated in patients with BMI ≥ 37.5. In patients with BMI < 37.5, average log MCP-1 values were signiﬁcantly elevated
in PDA patients when compared to IPMN patients. Within the IPMN group, higher log MCP-1 levels correlated with increased
age. Recursive partitioning analysis of IPMN versus PDA revealed a strategy of predicting characteristics of patients who are more
likely to have cancer. This strategy utilizes log MCP-1 as the primary factor and also utilizes smoking status, gender, and age.
Conclusion. MCP-1 is a promising biomarker in pancreatic cancer. The potential of using MCP-1 to distinguish PDA from IPMN
patients must be studied in larger populations to validate and demonstrate its eventual clinical utility.
1.Introduction
With an estimated 35, 420 deaths in 2008, pancreatic cancer
is the fourth leading cause of cancer death in the United
States [1]. Pancreatic cancer has an overall ﬁve-year survival
rate of only 4%, as fewer than 10% of patients’ tumors are
conﬁned to the pancreas at the time of diagnosis. In most
cases, the cancer has progressed to the point where surgical
resection is impossible. In a disease that is still considered
most often incurable, there remains a need for new strategies
for prevention and novel methods for early diagnosis.
One factor that is believed to have an important role in
the development of pancreatic cancer is obesity. Obesity is
deﬁned as a body mass index (BMI) > 30, and in the United
States, more than 30% of the population is classiﬁed as obese
[2]. Several studies have shown that the adipose tissue is an
active source of inﬂammatory mediators, suggesting that
obesity causes a chronic, low-level inﬂammatory state [3].
This is thought to contribute to the development of many
of the comorbidities found in obese patients, such as athe-
rosclerosis, diabetes, and cancer [4, 5]. This concept is sup-
portedbystudiesthathaveobservedalteredchemokinelevels
and deceased cancer mortality rates with weight loss or in
morbidly obese patients that have undergone bariatric sur-
gery [6, 7]. The mediators of chronic inﬂammation, such as
cytokines, free oxygen radicals, and chemokines, can cause
cellular injury, DNA damage, and increased proliferation,
creating a microenvironment in which carcinogenesis is fa-
vored [8, 9].
One of the key chemokines involved in the initiation
of inﬂammation is monocyte chemoattractant protein-1
(MCP-1). MCP-1 triggers chemotaxis and transendothelial
migration of monocytes by interacting with their membrane
CC(havetwoadjacentcysteineaminoacidsneartheiramino
terminus) chemokine receptor 2 (CCR2) [10, 11]. In squa-
mous cell carcinoma of the esophagus, MCP-1 expression2 Journal of Oncology
Table 1: Clinicopathological characteristics of PDA patients and MCP-1 levels.
PDA n = 62 % MCP-1 (pg/mL) mean ± SEM P value Survival at 12 months P value
Average age (yrs) 64.7
<60 (mean 52.9) 20 211.1 ± 68.37 0.12 83% 0.9
>60 (mean 70.2) 42 232.91 ± 51.69 74%
M 28 45 209.1 ± 50.5 0.9 85% 0.5
F 34 55 239.7 ± 62.9 67.9%
BMI
Normal weight (<25) 20 32 174.3 ± 30.7 77.7%
Overweight (25–29.9) 28 45 227.8 ± 55.3 0.09 75.7% 0.08
Obese (>30) 14 23 277.5 ± 141 71.3%
AJCC stage
I 5 8 69.12 ± 22.04 80%
II 46 74 228.43 ± 35.5 0.62 75% 0.4
III-IV 11 18 104.52 ± 15.6 62%
Grade
G1 8 13 280.15 ± 119.6 83%
G2 37 60 186.99 ±102.63 0.34 80% 0.5
G3-G4 17 27 302.63 ± 38.82 65%
Lymph nodes
N0 7 11 106.08 ± 30.37 83%
N1-N2 16 26 155.04 ± 26.77 80%
N3-N5 17 27 321.82 ± 85.19 0.07 63% 0.06
>N6 22 36 241.16 ± 91.066 50%
in cancer cells was correlated with venous invasion, distant
metastasis, and lymph node metastasis [12]. In addition,
MCP-1 was demonstrated to act as a potent chemotactic fac-
tor for myeloma cells [13, 14]. MCP-1 gene transfer has been
shown to enhance the metastatic potential of cancer cells
with increased neovascularization [15]. To date, most studies
in cancer have focused on MCP-1 tissue expression while
only a few have investigated the clinical utility of its serum
levelmeasurements.Withtheexceptionofafewpublications
oncervicalandovariancancers[16,17],whichshowedacor-
relation between MCP-1 systemic levels and cancer progres-
sion, no studies have evaluated MCP-1 serum levels in corre-
lation with PDA risk factors, such as obesity. This, in associa-
tion with other known pancreatic cancer risk factors, such as
ageandsmoking,maycontributetopredictingwhichpatient
population is more at risk to develop pancreatic cancer [18].
In this study, we investigated the relationship between
increased body weight and BMI in pancreatic cancer patients
and the circulating levels of MCP-1. We also evaluated
whether MCP-1 serum levels could serve as diﬀerentiation
marker for benign and malignant lesions. In this respect
we examined MCP-1 serum levels in PDA patients and in
patients with benign IPMNs.
2.MaterialsandMethods
2.1. Patients. This retrospective study included 89 patients
with pancreatic lesions who underwent pancreatic resection.
Blood was collected by venous puncture prior to surgery
from patients who underwent surgical resection at Thomas
Jeﬀerson University Hospital between 2005 and 2008. Serum
samples were prepared and stored at −80◦C until analyzed.
Sixty-two patients had pathologically conﬁrmed invasive
PDA, and twenty-seven had intraductal papillary mucinous
neoplasms (IPMNs). Clinical data were obtained from
Thomas Jeﬀerson University Hospital electronic medical re-
cords and from patients charts. All patients signed an ap-
propriate consent form. The study was approved by the
Institutional Review Board at Thomas Jeﬀerson University.
Clinical data, tumor characteristics, and AJCC staging of
these patients are shown in Table 1.
2.2. Methods. Serum concentrations of MCP-1 were mea-
sured using commercially available human MCP-1-speciﬁc
enzyme-linked immunosorbent assays (ELISAs) (R&D Sys-
tems, Minneapolis, MN) according to the manufacturer’s
protocol. Spectrophotometric evaluation of MCP-1 levels
was analyzed by Synergy HT multidetection Microplate
reader (BioTeck, Winooski, VT).
2.3. Statistical Analysis. Multivariable logistic regression
analysis was used to determine the association of clinical
factors and the protein MCP-1 with pancreatic cancer status.
MCP-1 protein expression was analyzed ﬁrst as raw levels
then in a logarithmic scale, in order to achieve a symmetric
distribution. An assessment of sensitivity and speciﬁcity of
the multivariable logistic regression model was completed
using receiver-operating characteristic (ROC) methods. As
an alternative approach, recursive partitioning analysis was
used in two ways, ﬁrst to demonstrate the relationshipJournal of Oncology 3
Table 2: Clinicopathological characteristics of IPMN patients and MCP-1 levels.
IPMN N = 27 % MCP-1 (pg/mL) mean ± SEM P value
Average age (yrs) 66.6
<60 (mean 53.3) 9 33 87.9±17.6 0.09
>60 (mean 72.8) 18 67 142.7± 17.7
M 7 26 152.9 ± 21.9 0.12
F 20 74 113.9 ± 14.3
BMI
Normal weight (<25) 10 37 80 ± 14.1
Overweight (25–29.9) 10 37 150 ± 17.7 0.34
Obese (>30) 7 26 132 ± 30
of MCP-1 with demographic and clinical characteristics,
and second to demonstrate the overall diﬀerences between
demographic, clinical, and MCP-1 characteristics of patients
with pancreatic cancer and patients with benign pancreatic
lesions (IPMNs). Sensitivity and speciﬁcity of the resulting
algorithm to determine cancer versus benign pathology was
completed using the standard deﬁnitions of these measures.
A linear mixed model was used to compare mean values of
MCP-1 across deﬁned subgroups from the recursive parti-
tioning model. Linear contrasts of the least squares means
were used to compare across recursive-partitioning deﬁned
subgroups. No adjustment for multiple comparisons was
made to the P values. Probabilities ≤ 0.05 were considered
signiﬁcant. Analysis was completed using R version 2.9.2 and
SAS version 9.2 (SAS; Campus Drive, Cary, NC).
3. Results
3.1. Patient Characteristics. The patients’ data and clinico-
pathological parameters are summarized in Table 1. The av-
erage age at diagnosis was 64.7 years (range 41 to 80 years)
for PDA patients and 66.6 years (44–81 years) for IPMNs
patients. The average duration of followup was 15.2 months
(range, 1.5–31 months). BMI was calculated as weight in
kilograms divided by the square height in meters, based on
the patient’s preoperative admission data. The National
Heart, Lung, and Blood Institute’s deﬁnition for overweight
and obesity was used to classify the patients by their weight.
AB M I< 18.5 was classiﬁed as underweight; a BMI between
18.5 and24.9 wasclassiﬁed asnormal weight;a BMIbetween
25.0 and 29.9 was classiﬁed as overweight; a BMI > 30 was
classiﬁedasobese.ThemeanBMIforallpatientsinthisstudy
was 26.6kg/m2. Values of MCP-1 in pg/mL in each group are
seen in Tables 1 and 2.
3.2.MCP-1SerumLevelsinObesePatients. Values for MCP-1
were logarithmically transformed prior to signiﬁcance test-
ing, as their distributions were skewed. Recursive partition-
ing analysis of log MCP-1 indicates that log MCP-1 values
are elevated in patients with BMI ≥ 37.5 (average log MCP-
1 = 6.68). In patients with BMI < 37.5, elevated MCP-1
levels are seen in patients with cancer (average log MCP-1 =
4.94). In patients with benign lesions, log MCP-1 values
are elevated with age (age < 55, average log MCP-1 = 3.59;
age ≥ 55, average log MCP-1 = 4.81). Using contrasts from
the linear model, these mean diﬀerences were tested, with
results presented in Table 3.
3.3. MCP-1 Serum Levels, Patient Clinicopathological Parame-
ters, and the Presence of PDA Compared with Benign IPMN.
Recursive partitioning analysis of benign versus malignant
pathology reveals a strategy of predicting characteristics of
patients who are more likely to have cancer. This strategy
utilizes log MCP-1 as the primary factor and also utilizes
smokingstatus,gender,andage.Thealgorithmachieves95%
sensitivity and 59% speciﬁcity. As seen in Figure 1,r e c u r s i v e
partitioningdemonstratesthatthelowestlevelsoflogMCP-1
were obtained in benign nonobese patients under the age of
55 (log MCP-1 = 3.59). Benign nonobese patients 55 years
old and over had average log MCP-1 levels of 4.81, and
nonobese cancer patients had MCP-1 level of 4.94. Obese
patients, regardless of cancer status, had the highest level of
log MCP-1 (6.68).
3.4. MCP-1 Serum Levels and Cancer Predictability. Log
MCP-1inmultivariatelogisticregressionanalysiscontrolling
for gender, age, BMI, and quartiles of log MCP-1 was com-
pleted. As seen in Figure 2, patients within the highest quar-
tile of log MCP-1 were 6.2 times more likely to be pancreatic
cancer patients when compared to patients within the lowest
quartile of log MCP-1 (adjusted odds ratio 6.2, 95% conﬁ-
dence interval [1.1, 37.4], P = 0.04). The ROC curve result-
ing from this model could not identify a combination that
obtained both high sensitivity and high speciﬁcity.
4. Discussion
With the rising epidemic of obesity, several studies have
revealed that the chronic inﬂammatory changes associated
with obesity may explain some comorbidities in obese
patients and even the increased incidence of cancer in this
patient population [19, 20]. Cytokines and chemokines and
their receptors have been analyzed in cancer patients and
animal models to attempt to elucidate this link.
Chemokinesformasuperfamilyofsmall,inducible,proin-
ﬂammatorychemotacticcytokines.Theseproteinshavebeen
reported to be involved in a variety of immune and inﬂam-
matory responses, acting primarily as chemoattractants and4 Journal of Oncology
Table 3: Subgroups of levels of log MCP-1 as deﬁned by recursive partitioning. Data in diagonal cells represents least squares mean of the
speciﬁed subgroup, while unadjusted P values are provided in the oﬀ-diagonal cells.
BMI < 37.5,
diagnosis: benign,
age < 55
CI
BMI < 37.5,
diagnosis: benign,
age ≥ 55
CI BMI < 37.5,
diagnosis: cancer
CI BMI ≥ 37.5,
diagnosis: cancer
CI
BMI < 37.5,
diagnosis: benign,
age < 55
3.59 2.9–4.3
BMI < 37.5,
diagnosis: benign,
age ≥ 55
P = 0.003 4.81 4.5–5.1
BMI < 37.5,
diagnosis: cancer P<0.001 P = 0.46 4.94 4.8–5.1
BMI ≥ 37.5,
diagnosis: cancer P<0.001 P<0.001 P = 0.001 6.68 5.7–7.7
BMI < 37.5 BMI ≥ 37.5
As.factor (diagn) = Bngn As.factor (diagn) = Cncr
Age < 55 Age ≥ 55
3.59
n = 5
4.81
4.94
n = 60
n = 22
6.68
n = 2
Error: 0.768 CV 1.15 SE: 0.234 error:
Figure 1:Multivariatelogisticregressionanalysiswasusedtodeter-
mine the association of clinical factors and the protein MCP-1 with
pancreatic cancer status. An assessment of sensitivity and speciﬁcity
of this model was completed using receiver-operating characteristic
(ROC) methods. Recursive partitioning analysis was used to de-
monstrate the relationship of log MCP-1 with demographic and
clinical characteristics. The lowest levels of log MCP-1 were ob-
tained in benign nonobese patients under the age of 55 years (3.59).
Benign nonobese patients aged 55 years and over had average log
MCP-1 levels of 4.81, and nonobese cancer patients had log MCP-
1 levels of 4.94. Obese patients, regardless of cancer status, had the
highest level of log MCP-1 (6.68).
activators of speciﬁc leukocytes. MCP-1 is a member of the
C-C subfamily of chemokines and is expressed upon stimu-
lation in a wide variety of cells, such as mononuclear leuko-
cytes, ﬁbroblasts, endothelial and epithelial cells, smooth
muscle cells, melanocytes, and various tumor cells [21].
MCP-1 is a key element of the immunological response to
malignant growth, mainly via attraction and activation of
tumor-associated macrophages [22]. The presence of high
tumor levels of MCP-1 has been reported in several malig-
nancies in relation to tumor progression [11–15]. However,
no previous studies have examined serum levels of MCP-
1 in correlation with pancreatic cancer risk factors. To our
knowledge, this is the ﬁrst report (a) demonstrating a posi-
tive correlation between the level of a particular chemokine
andthesubjectBMIasariskfactorforPDAand(b)revealing
the potential validity of MCP-1 as a diﬀerentiation marker
for benign and malignant lesions.
Our data show that although raw value of MCP-1 did not
show signiﬁcance when correlated with the diﬀerent clinico-
pathological parameters in PDA (Table 1)o rI P M Np a t i e n t s
groups,patientswithBMI ≥37.5averagedhigherlogMCP-1
values than patients with a BMI < 37.5 when using recursive
partitioning analysis. These data support the ﬁndings of
other studies showing correlation of high circulating MCP-
1 levels in obese individuals [23, 24] and in type 2 diabetes
[25]. However, previous studies have shown that serum
levels of MCP-1 are decreased after weight loss in obese
healthy individuals [24, 25]. Due to the late presentation of
pancreaticcancer,manypatientsmayhavealreadylostacon-
siderable amount of weight by the time they have presented
for surgical intervention. Therefore, our patients’ serum
MCP-1 levels during their peak BMI may have decreased by
the time of their pancreatic resection. Thus, based on our
presentdata,wecannotconcludethatweightlossduetoPD A
itself may be associated with reduced MCP-1 levels in PDA
patients and future studies are needed to test this hypothesis.
Our data also show that, in the less obese patients, there
washighassociationbetweenelevatedBMIandincreasedlog
MCP-1 levels in PDA patients compared to the nonsignif-
icant association in patients with benign IPMNs. In those
patients with benign lesions, higher values were seen with
age >55. These ﬁndings might be independent of the benign
lesion itself, since previous studies have reported increased
circulating levels of MCP-1 with advanced age [26].
Previous studies have shown the validity of MCP-1 as a
diﬀerentiationmarkerbetweenbenignandmalignantlesions
ingliomas[27]andovariancancerpatients[28].Inourstud-
ies, using multivariate logistic regression analysis we exam-
ined MCP-1 in relation to other clinical characteristics and
risk factors to evaluate which groups had an increased rate
of PDA. First, we found that patients within the highest
quartile of log MCP-1 were 6.2 times more likely to have
pancreatic cancer than those patients within the lowest logJournal of Oncology 5
< 5.057
Benign
Benign
Benign
Benign
6/2
4/21
2/22
2/6
≥ 4.402 < 4.402
< 4.969 ≥ 4.969
Age < 77.5 Age ≥ 77.5
Cancer
Cancer
Cancer
Cancer
3/9 2/0
2/0
6/1
Error: 0.519 CV error: 1.33 SE: 0.171
Miss class rate: null = 0.307 :model = 0.159 : CV = 0.409
Gender = female Gender = male
As. factor (smoke) = 0 As. factor (smoke) = 1
log MCP ≥ 5.272
log MCP
log MCP log MCP
log MCP log MCP
log MCP ≥ 5.057
log MCP < 5.272
Figure 2: Recursive partitioning analysis was used to demonstrate the overall diﬀerences between demographic, clinical, and log MCP-1
characteristics of patients with PDA and patients with benign IPMN. Sensitivity and speciﬁcity of the resulting algorithm to determine
cancer versus benign patients was completed using the standard deﬁnitions of these measures. Word at end of node demonstrates that
the algorithm predicts either Benign or Cancer for the subgroup and graph then represents how many Benign/Cancer patients are in each
subgroup. Standard logistic regression analysis utilizing log MCP-1 could not attain this level of sensitivity and speciﬁcity combined, rather
it could achieve high values of one of these metrics at the expense of the other.
MCP-1. In the patients with the lower quartile of log MCP-1,
increased rate of cancer was seen in those with known risk
factors for pancreatic cancer, such as smoking or male sex.
It remains to be determined, however, whether MCP-1 could
serve as a comparable marker independent of the established
marker for pancreatic cancer CA 19–9. These studies that
are currently ongoing in our laboratory are important to
document the validity of MCP-1 as a possible candidate in
the ongoing eﬀorts to ﬁnd adequate combined screening
systems for high risk patients and to monitor the prognosis
of PDA patients following surgical resection.
A single study has been published so far regarding the
prognostic value of MCP-1 serum levels in PDA. Christian-
sen et al. (2005) [27] reported that higher MCP-1 serum lev-
els correlate with increased macrophage inﬁltration of pan-
creaticcancertissueandwithafavorableprognosisandover-
all survival. However, it has also been reported that mono-
cyte/macrophage inﬁltration of malignant tissue may pro-
mote tumor growth by producing various chemokines [8, 9].
In our series, MCP-1 serum levels showed no clear inﬂu-
ence on the patients’ prognosis regarding disease-free and
overall survival. Although the cellular sources of circulating
MCP-1 are not determined, our data indicate that MCP-1 is
a promising biomarker that might play a functional role in
the natural history of PDA, especially in obese patients.
4.1. Study Limitations. Since this was a pilot study, we fo-
cused only on our patients’ population. A larger study that
includes age and weight-matched healthy volunteers and a
larger number of patients is currently under preparation.
Comparative data on CA-19–9 and other markers of inﬂam-
mation, such as C-reactive protein, could be extremely valu-
able to determine how MCP-1 levels compare to other fac-
tors. Studies to address these deﬁciencies are currently ongo-
ing in our laboratory.
Becausetheﬁndingsof thisstudyarelimited tosurgically
resected patients with PDA or IPMN, the temporal relation-
ship between MCP-1 level changes in the serum and the
progression of PDA remains unknown. The absence of sig-
niﬁcant correlations between clinicopathological parameters
and the circulating MCP-1 levels should be interpreted with
caution. The sample size was relatively small, and our follow
upperiodwasrelativelyshortforassociationstudiesandmay
have mitigated against demonstrating statistical associations.
Moreover, further study of this protein in diﬀerent benign
andunresectablemalignantlesions,tounderstandthenature6 Journal of Oncology
of the relationship of its elevation with age and with highest
levels of obesity, will assist with the full development of the
potential clinical usage of this marker.
5. Conclusion
The promise demonstrated using MCP-1 plus other patient
characteristicstodistinguishpatientswithbenignversusma-
lignant disease must be studied in larger populations to both
validate and demonstrate their eventual clinical utility.
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